Literature DB >> 12604535

Aminoglycoside nephrotoxicity: modeling, simulation, and control.

Florent Rougier1, Daniel Claude, Michel Maurin, Alexandre Sedoglavic, Michel Ducher, Stéphane Corvaisier, Roger Jelliffe, Pascal Maire.   

Abstract

The main constraints on the administration of aminoglycosides are the risks of nephrotoxicity and ototoxicity, which can lead to acute, renal, vestibular, and auditory toxicities. In the present study we focused on nephrotoxicity. No reliable predictor of nephrotoxicity has been found to date. We have developed a deterministic model which describes the pharmacokinetic behavior of aminoglycosides (with a two-compartment model), the kinetics of aminoglycoside accumulation in the renal cortex, the effects of aminoglycosides on renal cells, the resulting effects on renal function by tubuloglomerular feedback, and the resulting effects on serum creatinine concentrations. The pharmacokinetic parameter values were estimated by use of the NPEM program. The estimated pharmacodynamic parameter values were obtained after minimization of the least-squares objective function between the measured and the calculated serum creatinine concentrations. A simulation program assessed the influences of the dosage regimens on the occurrence of nephrotoxicity. We have also demonstrated the relevancy of modeling of the circadian rhythm of the renal function. We have shown the ability of the model to fit with 49 observed serum creatinine concentrations for a group of eight patients treated for endocarditis by comparison with 49 calculated serum creatinine concentrations (r(2) = 0.988; P < 0.001). We have found that for the same daily dose, the nephrotoxicity observed with a thrice-daily administration schedule appears more rapidly, induces a greater decrease in renal function, and is more prolonged than those that occur with less frequent administration schedules (for example, once-daily administration). Moreover, for once-daily administration, we have demonstrated that the time of day of administration can influence the incidence of aminoglycoside nephrotoxicity. The lowest level of nephrotoxicity was observed when aminoglycosides were administered at 1:30 p.m. Clinical application of this model might make it possible to adjust aminoglycoside dosage regimens by taking into account both the efficacies and toxicities of the drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604535      PMCID: PMC149325          DOI: 10.1128/AAC.47.3.1010-1016.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Aminoglycoside nephrotoxicity: do time and frequency of administration matter?

Authors:  D Beauchamp; G Labrecque
Journal:  Curr Opin Crit Care       Date:  2001-12       Impact factor: 3.687

2.  Circadian rhythm analysis when output is collected at intervals.

Authors:  J H Ware; R E Bowden
Journal:  Biometrics       Date:  1977-09       Impact factor: 2.571

3.  Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Authors:  M J Rybak; B J Abate; S L Kang; M J Ruffing; S A Lerner; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Renal clearance and tissue accumulation of gentamicin.

Authors:  J J Schentag; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

5.  Nephrotoxicity of gentamicin.

Authors:  J C Kosek; R I Mazze; M J Cousins
Journal:  Lab Invest       Date:  1974-01       Impact factor: 5.662

6.  Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside.

Authors:  K R Murry; P S McKinnon; B Mitrzyk; M J Rybak
Journal:  Pharmacotherapy       Date:  1999-11       Impact factor: 4.705

Review 7.  Time-patterned drug administration: insights from a modeling approach.

Authors:  Albert Goldbete; Daniel Claude
Journal:  Chronobiol Int       Date:  2002-01       Impact factor: 2.877

8.  Early effects of gentamicin, tobramycin, and amikacin on the human kidney.

Authors:  M E De Broe; G J Paulus; G A Verpooten; F Roels; N Buyssens; R Wedeen; F Van Hoof; P M Tulkens
Journal:  Kidney Int       Date:  1984-04       Impact factor: 10.612

9.  In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats.

Authors:  R A Giuliano; G A Verpooten; L Verbist; R P Wedeen; M E De Broe
Journal:  J Pharmacol Exp Ther       Date:  1986-02       Impact factor: 4.030

10.  Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity.

Authors:  W C Elliott; D C Houghton; D N Gilbert; J Baines-Hunter; W M Bennett
Journal:  J Lab Clin Med       Date:  1982-10
View more
  17 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

3.  Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

Authors:  Clement Mugabe; Majed Halwani; Ali O Azghani; Robert M Lafrenie; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

5.  Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients.

Authors:  Carolina Consuelo Llanos-Paez; Christine Staatz; Stefanie Hennig
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

6.  Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.

Authors:  Kevin J Downes; Min Dong; Tsuyoshi Fukuda; John P Clancy; Christopher Haffner; Michael R Bennett; Alexander A Vinks; Stuart L Goldstein
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

7.  Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Reiko Sato; Yusuke Tanigawara; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

8.  Ototoxic destruction by co-administration of kanamycin and ethacrynic acid in rats.

Authors:  Hong Liu; Da-lian Ding; Hai-yan Jiang; Xue-wen Wu; Richard Salvi; Hong Sun
Journal:  J Zhejiang Univ Sci B       Date:  2011-10       Impact factor: 3.066

9.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

Review 10.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.